Risk stratification is the basis for prognostic assessment and therapeutic guidance in Pulmonary Hypertension.

The “Risco na PH” application facilitates the use of risk stratification strategies for Pulmonary Arterial Hypertension, according to scientific publications:

- French Registry of Pulmonary Hypertension (FPHN);
- Prospective registry of newly initiated therapies for pulmonary hypertension (COMPERA 2.0);
- Registry to assess the risk of early and long-term management in PAH (REVEAL 2.0 and REVEAL Lite 2);
- ESC/ERS 2022 guidelines for the diagnosis and treatment of pulmonary hypertension.

The responsibility for determining the therapeutic approach for each patient lies with the physician and his team. The application only facilitates the use of risk assessment strategies. The information presented by the application should not be used in isolation.

Bayer is not responsible for the inappropriate use of the information provided.

PP-ADE-BR-0245-1-03-2023